On June 24, BeiGene (06160.HK) rose 3.05% in regular trading, trading at 165.8 HKD/share, with turnover of 53.15 million HKD.

On the news front, BeiGene recently announced that its supplemental Biologics License Application for Tevimbra targeting esophageal squamous cell carcinoma has been accepted by the U.S. FDA, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.

Within the Biotechnology sector, the overall tone was positive. Among individual stocks, Innovent Biologics rose 2.55%, Akeso rose 1.64%, 3SBio rose 0.18%, and Ascletis gained 0.10%, with sector linkage providing additional support for BeiGene's continued upward momentum following a technical rebound from the prior session's pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)